The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2022 | EBMT-EHA CAR T-cell highlights: new indications, new CAR-Ts & the microbiota’s impact on outcomes
There were many interesting updates on chimeric antigen receptor T-cell (CAR-T) therapies presented at this year’s EBMT-EHA CAR T-cell Meeting. In this video, Michael Loschi, MD, PhD, University Hospital of Nice, Cote d’Azur University, Nice, France, shares his highlights from the meeting. Dr Loschi talks on the long-awaited developments in CAR-Ts for acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). He also mentions advances in dual-targeting CAR-Ts and induced pluripotent stem cell (IPSC)-derived CAR-Ts, as well as updates on the role of the microbiota in CAR-T therapy outcomes. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
